阿尔茨海默病中的粉样β:结构,毒性,分布,治疗和前景
Yifan Yu1,2,3, Shilong Yu1,2,3, Giuseppe Battaglia1,2,3
1Institute for Bioengineering of Catalunya (IBEC) The Barcelona Institute of Science and Technology (BIST), Barcelona (Spain), Carrer Baldiri I Reixac Barcelona Spain.
Ibrain
|September 30, 2024
概括
在阿尔茨海默氏症 (AD) 中的粉样蛋白-β (Aβ) 清除受到争议. 最近对抗Aβ药物的批准将重点转移到Aβ的结构,病理和向治疗.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 粉样β (Aβ) 是阿尔茨海默病 (AD) 的一个关键生物标志物.
- Aβ清除的治疗益处仍然不确定,影响药物开发.
- 莱卡尼马布的批准标志着针对Aβ的AD治疗的转折点.
研究的目的:
- 审查Aβ的分子结构和病理学.
- 探索影响Aβ表达的因素.
- 分析目前和新兴的针对阿尔茨海默病的Aβ向药物疗法.
主要方法:
- 文献综述和对Aβ现有研究的分析.
- 关于Aβ结构,病理和表达的数据的整合.
- 对临床和临床前Aβ向药物研究的评估.
主要成果:
- 详细介绍了Aβ的结构属性和病理作用.
- 阐明了Aβ表达水平的决定因素.
- 介绍了针对Aβ的药物治疗方法的全面概述.
结论:
- Aβ是阿尔茨海默病的可行的治疗点.
- 纳米粒子构造为AD诊断和治疗提供了潜在的优势.
- 需要进一步的研究来优化针对Aβ的策略.
更多相关视频
09:31Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
10.6K
08:25Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
Published on: April 19, 2021
3.2K
相关概念视频
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
